蛋白酪氨酸激酶-2在妇科肿瘤中的作用

doi:10.16352/j.issn.1001-6325.2025.08.1098

基础医学与临床 ›› 2025, Vol. 45 ›› Issue (8): 1098-1102.doi: 10.16352/j.issn.1001-6325.2025.08.1098

蛋白酪氨酸激酶-2在妇科肿瘤中的作用

秦怡, 王晓燕^*

山西医科大学第二临床医学院妇产科,山西太原 030000

收稿日期:2025-03-31 修回日期:2025-05-30 出版日期:2025-08-05 发布日期:2025-07-11
通讯作者: ^*Wangxiaoyan369@sina.com
基金资助:
国家肿瘤区域医疗中心科教培育基金博导硕导伴飞基金(SD2023015)

Role of protein tyrosine kinase-2 in gynecological tumors

QIN Yi, WANG Xiaoyan^*

Department of Obstetrics and Gynecology, the Second Clinical Medical College of Shanxi Medical University, Taiyuan 030000, China

Received:2025-03-31 Revised:2025-05-30 Online:2025-08-05 Published:2025-07-11
Contact: ^*Wangxiaoyan369@sina.com

摘要/Abstract

摘要： 蛋白酪氨酸激酶-2(PTK2)是一种重要的非受体酪氨酸激酶,通过其激酶依赖和非依赖双重途径发挥功能。PTK2可以通过整合素介导的黏附信号转导,激活下游关键通路,调控肿瘤细胞增殖、迁移和上皮-间质转化(EMT)。此外,它还可以重塑肿瘤微环境,促进肿瘤转移、血管生成和免疫逃逸。大量研究表明,PTK2在多种妇科癌症中高表达,其表达水平与肿瘤分期、不良预后及临床耐药显著相关。综上,PTK2有望成为未来妇科恶性肿瘤新的治疗靶点和预后标志物。

关键词: 妇科恶性肿瘤, 黏着斑激酶, 肿瘤转移, 信号通路, PTK2抑制剂

Abstract: Protein tyrosine kinase 2 (PTK2) is an important non-receptor tyrosine kinase that functions through both kinase-dependent and kinase-independent pathways. PTK2 can activate the downstream pathways through integrin-mediated adhesion signal transduction, regulating tumor cell proliferation, migration and epithelial-mesenchymal transition (EMT). Additionally, PTK2 can also remodel the tumor microenvironment, promote tumor metastasis, angiogenesis and immune escape. A large number of studies have shown that PTK2 is highly expressed in various gynecological cancers, and its expression level is significantly associated with tumor stage, poor prognosis and clinical drug resistance. Therefore, PTK2 is expected to serve as a novel therapeutic target and prognostic biomarker for gynecological malignancies in the future.

Key words: malignant gynecological tumor, focal adhesion kinase, tumor metastasis, signal pathway, PTK2 inhibitor

中图分类号:

秦怡, 王晓燕. 蛋白酪氨酸激酶-2在妇科肿瘤中的作用[J]. 基础医学与临床, 2025, 45(8): 1098-1102.

QIN Yi, WANG Xiaoyan. Role of protein tyrosine kinase-2 in gynecological tumors[J]. Basic & Clinical Medicine, 2025, 45(8): 1098-1102.

参考文献

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2024,74:229-263.
[2] Hu HH, Wang SQ, Shang HL, et al. Roles and inhibitors of FAK in cancer: current advances and future directions[J].Front Pharmacol,2024,15:1274209.doi: 10.3389/fphar.2024.1274209.
[3] Pomella S, Cassandri M, Braghini MR, et al. New insights on the nuclear functions and targeting of FAK in cancer[J]. Int J Mol Sci, 2022, 23: 1998.doi: 10.3390/ijms23041998.
[4] Webb ER, Black A, Barth ND, et al. The integrin adhesome and control of anti-tumour immunity[J]. Biochem Soc Trans, 2024, 52: 2455-2468.
[5] Chen S, He T, Zhong Y, et al. Roles of focal adhesion proteins in skeleton and diseases[J]. Acta Pharm Sin B, 2023, 13:998-1013.
[6] Song X, Xu H, Wang P, et al. Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation[J]. J Hepatol, 2021, 75: 888-899.
[7] Sharma BK, Mureb D, Murab S, et al. Fibrinogen activates focal adhesion kinase (FAK) promoting colorectal adenocarcinoma growth[J]. J Thromb Haemost, 2021, 19: 2480-2494.
[8] Raji L, Tetteh A, Amin ARMR. Role of c-Src in carcinogenesis and drug resistance[J]. Cancers (Basel), 2023, 16: 32.doi:10.3390/concers16010032.
[9] Huang YH, Chen HK, Hsu YF, et al. Src-FAK signaling mediates interleukin 6-induced HCT116 colorectal cancer epithelial-mesenchymal transition[J]. Int J Mol Sci, 2023, 24: 6650.doi: 10.3390/ijms24076650.
[10] Pan R, Yu Y, Zhu H, et al. RSPO2 promotes progression of ovarian cancer through dual receptor-mediated FAK/Src signaling activation[J]. iScience, 2022, 25: 105184. doi: 10.1016/j.isci.2022.105184.
[11] Canel M, Sławińska AD, Lonergan DW,et al. FAK sup-presses antigen processing and presentation to promote immune evasion in pancreatic cancer[J]. Gut, 2023, 73: 131-155.
[12] Wu HJ, Hao M, Yeo SK, et al. FAK signaling in cancer-associated fibroblasts promotes breast cancer cell migration and metastasis by exosomal miRNAs-mediated intercellular communication[J]. Oncogene, 2020, 39: 2539-2549.
[13] Huang C, Wang Y, Huang JH, et al. Sema3A drastically suppresses tumor growth in oral cancer xenograft model of mice[J]. BMC Pharmacol Toxicol, 2017, 18:55.doi: 10.1186/s40360-017-0163-4.
[14] 候壹颖,魏芳. BUB1B与妇科恶性肿瘤[J]. 基础医学与临床,2024,44:1717-1721.
[15] 封菊,苑中甫,邱海峰. RNA干扰FAK表达抑制宫颈癌细胞侵袭、迁移能力的研究[J]. 癌症进展,2018,16:179-182.
[16] Zhang J, Li X, Zhou Y, et al. FNBP1 facilitates cervical cancer cell survival by the constitutive activation of FAK/PI3K/AKT/mTOR signaling[J]. Cells, 2023, 12: 1964.doi: 10.3390/cells12151964.
[17] Du Q, Liu P, Zhang C, et al. FASN promotes lymph node metastasis in cervical cancer via cholesterol reprogramming and lymphangiogenesis[J]. Cell Death Dis, 2022, 13: 488.doi: 10.1038/s41419-022-04926-2.
[18] Gong H, Zhao L, Liu J. Protective effect of tretinoin on cervical cancer growth and proliferation through downregulation of pFAK2 expression[J]. Environ Toxicol, 2024, 39: 2732-2740.
[19] Dong P, Xiong Y, Konno Y, et al. Long non-coding RNA DLEU2 drives EMT and glycolysis in endometrial cancer through HK2 by competitively binding with miR-455 and by modulating the EZH2/miR-181a pathway[J]. J Exp Clin Cancer Res, 2021, 40: 216.doi: 10.1186/s13046-021-02018-1.
[20] Lopez-Mejia IC, Pijuan J, Navaridas R, et al. Oxidative stress-induced FAK activation contributes to uterine serous carcinoma aggressiveness[J]. Mol Oncol, 2023, 17: 98-118.
[21] Huang YH, Wang WL, Wang PH, et al. EXOSC5 maintains cancer stem cell activity in endometrial cancer by regulating the NTN4/integrin β1 signalling axis[J]. Int J Biol Sci, 2024, 20: 265-279.
[22] Demirkiran C, Greenman M, Bellone S, et al. Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas[J]. Gynecol Oncol, 2024, 187: 12-20.
[23] 霍茜瑜, 任彦松. 纤维连接蛋白在卵巢癌迁移侵袭中作用的研究进展[J]. 现代肿瘤医学, 2024, 32: 1935-1938.
[24] Ozmadenci D, Shankara Narayanan JS, Andrew J, et al. Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis[J]. Proc Natl Acad Sci USA, 2022, 119: e2117065119.doi: 10.1073/pnas.2117065119.
[25] Xie G, Zhang Y, Ma J, et al. Exosomal AHSG in ovarian cancer ascites inhibits malignant progression of ovarian cancer by p53/FAK/Src signaling[J]. Transl Cancer Res, 2024, 13: 5365-5380.
[26] Wu X, Wang J, Liang Q, et al. Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment[J]. Biomed Pharmacother, 2022, 151: 113116.doi: 10.1016/j.biopha.2022.113116.

蛋白酪氨酸激酶-2在妇科肿瘤中的作用

Role of protein tyrosine kinase-2 in gynecological tumors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	高彦东, 边步荣, 王波. 异丙酚减轻结扎脊神经诱导的大鼠神经病理性疼痛[J]. 基础医学与临床, 2025, 45(8): 1028-1033.
[2]	贾纯亮, 梁磊, 李翰嵩, 王剑, 张磊, 李青科, 姚远. 灯盏花乙素抑制人胃癌细胞系MGC803增殖和迁移[J]. 基础医学与临床, 2025, 45(8): 1048-1053.
[3]	于华惠, 杜智勇, 焦晓璐, 吕倩雯, 杨云云, 韩丽杰, 秦彦文. 血管生成素样蛋白8通过激活p53信号通路促进平滑肌细胞凋亡[J]. 基础医学与临床, 2025, 45(7): 882-888.
[4]	吴雪丽, 杨玉容, 保永莉, 吴汝成, 王莉莎, 陈阳. HAP1细胞有丝分裂过程中的动态转录物组研究[J]. 基础医学与临床, 2025, 45(6): 786-792.
[5]	秋昱翀, 杜文静. 苹果酸酶2通过调控SHCBP1促进肝癌的发生发展[J]. 基础医学与临床, 2025, 45(6): 741-747.
[6]	武波, 郭昊, 钟曌, 刘军芳, 王琦, 郭继勃. 过表达miR-101抑制JAK2/STAT3信号通路减缓急性心肌梗死模型大鼠心室重构[J]. 基础医学与临床, 2025, 45(3): 281-289.
[7]	邢雨润, 陈苏颖, 屠金恒, 何伯圣. 肠缺血/再灌注损伤对远端器官功能的影响[J]. 基础医学与临床, 2025, 45(3): 395-398.
[8]	楼海均, 孟·孟根, 张振宇, 童卓云, 乌都木丽. 跨膜蛋白33在肿瘤发生发展中的作用[J]. 基础医学与临床, 2025, 45(2): 258-262.
[9]	靳高超, 邢盼盼, 王玉, 刘波. 乌司他丁联合生长抑素减轻急性胰腺炎大鼠肠道损伤[J]. 基础医学与临床, 2025, 45(2): 203-209.
[10]	庞昀婷, 任晓爽, 包涵, 孟凡青, 石枫. 左西孟旦减轻模型大鼠离体心脏停灌/再灌注损伤[J]. 基础医学与临床, 2025, 45(1): 65-69.
[11]	肖艳红, 姜明东, 林叶远, 冉灿, 梁博. 灯盏花乙素抑制人前列腺癌细胞系PC-3的增殖和迁移[J]. 基础医学与临床, 2024, 44(9): 1229-1235.
[12]	蒋苏, 吕新翔, 崔艳红, 吕李婷, 李东霞. 吴茱萸碱对特应性皮炎模型大鼠的治疗作用[J]. 基础医学与临床, 2024, 44(9): 1256-1262.
[13]	金庆, 丁佑铭. FOXC1在消化系统癌发生发展中作用的研究进展[J]. 基础医学与临床, 2024, 44(7): 1049-1053.
[14]	高寅洁, 童安莉. 醛固酮产生腺瘤中细胞死亡和增殖机制[J]. 基础医学与临床, 2024, 44(6): 758-762.
[15]	徐璐, 张冬雨, 王瑞锋. 茯苓酸调节PI3K/AKT/NF-κB信号通路对大鼠幽门螺旋杆菌相关性胃炎的治疗作用[J]. 基础医学与临床, 2024, 44(4): 489-495.